size : | Price | Quantity | |
---|---|---|---|
5 mg | $50.00 | ||
25 mg | $200.00 |
Carfilzomib (868540-17-4) is a potent and irreversible proteasome inhibitor.1Synthetic analog of the microbial product epoxomcin.2 Compared to bortezomib it displays equal potency but greater selectivity for the chymotrypsin-like activity of the proteasome. In cell culture it is more cytotoxic than bortezomib and hematologic tumor cells exhibit greater sensitivity than solid tumor cells. Treatment of cells with carfilzomib results in the accumulation of proteasome substrates and induction of cell cycle arrest and/or apoptosis.3 Effective against multiple myeloma.4 Active in vivo.
References/Citations:
1) Bennett and Kirk (2008) Development of proteasome inhibitors in oncology and autoimmune diseases; Curr. Opin. Drug Disc. Dev. 11 616
2) Hanada et al. (1992), Epoxomicin, a new antitumor agent of microbial origin; J. Antibiot. (Tokyo), 45 174
3) Demo et al. (2007) Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome; Cancer Res. 67 6383
4) Kuhn et al. (2007), Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma; Blood, 110 328
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Carfilzomib (868540-17-4) is a potent and irreversible proteasome inhibitor.1Synthetic analog of the microbial product epoxomcin.2 Compared to bortezomib it displays equal potency but greater selectivity for the chymotrypsin-like activity of the proteasome. In cell culture it is more cytotoxic than bortezomib and hematologic tumor cells exhibit greater sensitivity than solid tumor cells. Treatment of cells with carfilzomib results in the accumulation of proteasome substrates and induction of cell cycle arrest and/or apoptosis.3 Effective against multiple myeloma.4 Active in vivo.
References/Citations:
1) Bennett and Kirk (2008) Development of proteasome inhibitors in oncology and autoimmune diseases; Curr. Opin. Drug Disc. Dev. 11 616
2) Hanada et al. (1992), Epoxomicin, a new antitumor agent of microbial origin; J. Antibiot. (Tokyo), 45 174
3) Demo et al. (2007) Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome; Cancer Res. 67 6383
4) Kuhn et al. (2007), Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma; Blood, 110 328
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.